- Home
- ALZN vs SILO Comparison
ALZN vs SILO Comparison
Compare ALZN & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALZN
- SILO
- Stock Information
- Founded
- ALZN 2016
- SILO 2010
- Country
- ALZN United States
- SILO United States
- Employees
- ALZN 7
- SILO N/A
- Industry
- ALZN Medicinal Chemicals and Botanical Products
- SILO Apparel
- Sector
- ALZN Health Care
- SILO Consumer Discretionary
- Exchange
- ALZN Nasdaq
- SILO Nasdaq
- Market Cap
- ALZN 9.0M
- SILO 8.0M
- IPO Year
- ALZN 2021
- SILO N/A
- Fundamental
- Price
- ALZN $2.44
- SILO $0.54
- Analyst Decision
- ALZN Strong Buy
- SILO
- Analyst Count
- ALZN 1
- SILO 0
- Target Price
- ALZN $42.00
- SILO N/A
- AVG Volume (30 Days)
- ALZN 132.0K
- SILO 840.4K
- Earning Date
- ALZN 12-11-2025
- SILO 11-12-2025
- Dividend Yield
- ALZN N/A
- SILO N/A
- EPS Growth
- ALZN N/A
- SILO N/A
- EPS
- ALZN N/A
- SILO N/A
- Revenue
- ALZN N/A
- SILO $72,102.00
- Revenue This Year
- ALZN N/A
- SILO $1.86
- Revenue Next Year
- ALZN N/A
- SILO N/A
- P/E Ratio
- ALZN N/A
- SILO N/A
- Revenue Growth
- ALZN N/A
- SILO N/A
- 52 Week Low
- ALZN $2.06
- SILO $0.40
- 52 Week High
- ALZN $15.21
- SILO $3.37
- Technical
- Relative Strength Index (RSI)
- ALZN 52.35
- SILO 39.69
- Support Level
- ALZN $2.32
- SILO $0.50
- Resistance Level
- ALZN $2.53
- SILO $0.62
- Average True Range (ATR)
- ALZN 0.14
- SILO 0.05
- MACD
- ALZN 0.01
- SILO -0.01
- Stochastic Oscillator
- ALZN 69.83
- SILO 54.64
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.